Renal Outcomes with Obinutuzumab and Voclosporin in Lupus Nephritis (ERA 2026) - Apr 13, 2026 - Abstract #1385; Pres time: Jun 4, 2026; 03:03 PM - 03:09 PM; Location: Focussed Oral Room 2; "The 12-month obinutuzumab response rate appears broadly consistent with REGENCY, though CRR i n our cohort was lower than reported in the trial; comparison with voclosporin trial outcomes is limited by small numbers and reduced follow-up in our cohort. Image"
Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Respiratory Diseases
|
|
Meera Patel 1; Soon Chin Toh 2; Aine Burns 1; Alan Salama 1; Sally Hamour 1; Vikram Joseph 2; Maria Leandro 2; David Isenberg 2; Ruth Pepper 1,2
|